Biotech Qureight raises £15m led by Molten Ventures with Hargreave Hale
This article covers Qureight, a biotech startup, which has raised £15m in a growth funding round to scale its AI imaging platform for clinical trials in lung and heart disease. The financing is being used to build an AI imaging laboratory and expand its 3D chest imaging Foundation Model to support drug developers, clinical trial sites and the development of imaging biomarkers for respiratory and cardiac indications.
Qureight, a biotech startup, has raised £15 million in a growth funding round to scale its AI imaging platform for clinical trials in lung and heart disease. The company said the financing is being used to build an AI imaging laboratory and to expand its 3D chest imaging Foundation Model, a move it argues will speed model development and broaden the range of diseases the platform can support.
Why it matters
Clinical imaging remains an under‑optimised part of many drug trials, despite its potential to deliver quantitative endpoints and earlier signals of efficacy or toxicity. Qureight’s technology aims to standardise image handling across sites, deliver compartment‑specific biomarkers for lung disease and provide synthetic control arms to reduce the cost and length of studies. The global lung and heart clinical trials market is projected to reach USD 27.5 billion by 2030, which underlines commercial opportunity as well as demand from biopharma for more efficient, data‑driven trial tools.
Inside the product
Qureight combines global imaging CRO services with proprietary AI lung image biomarkers. The platform supports faster site onboarding and more consistent image handling, and the biomarkers quantify structural changes within lung compartments that indicate disease progression. Its data science suite includes synthetic control arms that can be used to compare investigational arms against matched historical cohorts, potentially reducing participant numbers and study duration.
The new capital is earmarked to fund an AI imaging laboratory to house Qureight’s 3D chest imaging Foundation Model, which the company says will reduce the data requirements and time needed to develop disease models. Qureight plans to extend beyond its existing lung fibrosis models into asthma, pulmonary hypertension, bronchiectasis and drug‑induced lung toxicity, while continuing development of its quantitative imaging analytics platform and expanding its commercial team.
Who are the investors?
The round was led by Molten Ventures, with participation from Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension. As part of the financing, Dr Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale have joined Qureight’s board.
In the announcement, Muhunthan Thillai, Co‑founder & CEO at Qureight, said:
We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials. We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world class team, to address a critical demand to accelerate clinical trials. Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.
In the announcement, Inga Deakin, Partner at Molten Ventures, said:
Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team's rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
Qureight’s leadership frames the raise as both a product and market expansion play: focus on reducing development time for AI models and broadening into adjacent lung indications and heart imaging. The company’s emphasis on combining CRO services with analytic models reflects a commercial strategy of embedding technology into existing trial workflows rather than selling point solutions.
The bigger picture
The funding sits at the intersection of two trends: growing investment into AI applied to clinical research, and rising demand from biopharma for more precise, imaging‑based endpoints. The deal also highlights how UK startups are positioning AI and real‑world data as tools to speed up trials, an area attracting attention from both venture and corporate capital.
This raise underscores continued momentum for UK and European biotech companies building specialised AI platforms for clinical trials, and it will be worth watching how regulators and sponsors respond as these tools move into pivotal studies.
They've invested in Qureight
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Molten Ventures( ) Molten Ventures focuses on technology-driven companies across various sectors. T... London  | ||||
 Hargreave Hale AIM VCT( ) Blackpool | ||||
 XTX Ventures( ) XTX Ventures focuses on investing in exceptional founders from Seed to Series B ... London | ||||
 Guiness Asset Management( ) Guinness Global Investors is an independent fund manager focusing on long-only e... London | ||||
 Meltwind( ) Meltwind Advisory LLP focuses on early-stage investments in the life sciences se... Cambridge | ||||
 Ascension Ventures( ) Ascension is a leading UK venture capital firm focused on empowering tech innova... London | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK